Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta‐analysis-Reference-Cited by-同舟云学术

Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta‐analysis

Published:2019-05-23 Issue:10 Volume:85 Page:2280-2291
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Fachi Mariana M.¹^ORCID,Tonin Fernanda S.¹^ORCID,Leonart Leticia P.¹^ORCID,Rotta Inajara²^ORCID,Fernandez‐Llimos Fernando³^ORCID,Pontarolo Roberto⁴^ORCID

Affiliation:

1. Pharmaceutical Sciences Postgraduate ProgrammeUniversidade Federal do Paraná Curitiba Brazil

2. Pharmacy Service, Hospital de ClínicasFederal University of Paraná Curitiba Brazil

3. Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of PharmacyUniversidade de Lisboa Lisbon Portugal

4. Department of PharmacyUniversidade Federal do Paraná Curitiba Brazil

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13933

Reference80 articles.

1. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

2. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

3. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia

4. What is treatment free remission in chronic myeloid leukemia?

5. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice;Cancers;2024-01-13

3. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis;Cancers;2023-08-31

4. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07

5. Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China;BMC Health Services Research;2023-06-19